Bayer HealthCare and Onyx Pharmaceuticals Inc. announced that a Phase III trial evaluating Nexavar tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer did not meet its primary endpoint of improving overall survival. An improvement in the secondary endpoint of progression-free survival was also observed.
The trial compared Nexavar plus best supportive care to placebo plus best supportive care. The safety and tolerability data were generally as anticipated. The MISSION study was conducted at over 150 sites in North America, South America, Europe, Africa and the Asia-Pacific region, including Japan.
For comments and feedback: editorial@rttnews.com